Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational lung cancer research Chuang, J. C., Neal, J. W. 2015; 4 (5): 639-641

View details for DOI 10.3978/j.issn.2218-6751.2015.03.06

View details for PubMedID 26629437

View details for PubMedCentralID PMC4630528